Drug Trial Radar · NCT00969709
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Oct 25, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
724
Actual
Start
Sep 2009
Primary completion
May 2011
Sponsor
- Lead sponsor
- Forest LaboratoriesAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Sep 1, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER fixed doses versus placebo in the treatment of outpatients with major depressive disorder.
Conditions
- Major Depressive Disorder
Interventions
Levomilnacipran ERDrug
Levomilnacipran ER, 40 mg, oral administration, in capsule form, once daily for 8 weeks.
Levomilnacipran ERDrug
Levomilnacipran ER, 80 mg, oral administration, in capsule form, once daily for 8 weeks.
Levomilnacipran ERDrug
Levomilnacipran ER, 120 mg, oral administration, in capsule form, once daily for 8 weeks.
PlaceboDrug
Matching placebo capsules, oral administration, once daily for 8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total ScoreTime frame: From Baseline to Week 8
Locations
38 sites in 1 country. Site status is shown where the registry gives one.
Forest Investigative Site
Phoenix, Arizona
Forest Investigative Site
Scottsdale, Arizona
Forest Investigative Site
Beverly Hills, California
Forest Investigative Site
Costa Mesa, California
Forest Investigative Site
Escondido, California
Forest Investigative Site
Oceanside, California
Forest Investigative Site
Sherman Oaks, California
Forest Investigative Site
Denver, Colorado
Forest Investigative Site
Cromwell, Connecticut
Forest Investigative Site
Coral Springs, Florida
Forest Investigative Site
Fort Myers, Florida
Forest Investigative Site
Hallandale, Florida
Forest Investigative Site
Jacksonville, Florida
Forest Investigative Site
Orlando, Florida
Forest Investigative Site
West Palm Beach, Florida
Forest Investigative Site
Hoffman Estates, Illinois
Forest Investigative Site
Wichita, Kansas
Forest Investigative Site
Baltimore, Maryland
Forest Investigative Site
Rockville, Maryland
Forest Investigative Site
Cherry Hill, New Jersey
Forest Investigative Site
Willingboro, New Jersey
Forest Investigative Site
Brooklyn, New York
Forest Investigative Site
Mount Kisco, New York
Forest Investigative Site
New York, New York
Forest Investigative Site
New York, New York
Forest Investigative Site
Staten Island, New York
Forest Investigative Site
Raleigh, North Carolina
Forest Investigative Site
Canton, Ohio
Forest Investigative Site
Portland, Oregon
Forest Investigative Site
Media, Pennsylvania
Forest Investigative Site
Norristown, Pennsylvania
Forest Investigative Site
Lincoln, Rhode Island
Forest Investigative Site
Memphis, Tennessee
Forest Investigative Site
Dallas, Texas
Forest Investigative Site
Dallas, Texas
Forest Investigative Site
San Antonio, Texas
Forest Investigative Site
Bellevue, Washington
Forest Investigative Site
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.